Showing results (91-100 of 154) with videos related to

Sort By:
Pageof 16
Infection & Chemotherapy|October 6, 2016
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical TrialsJun Yong Choi, Somnuek Sungkanuparph, Thanomsak Anekthananon, et al.
The Journal of Infectious Diseases|April 3, 2025
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or ZinlirvimabJoseph J Eron, Paul P Cook, Megha L Mehrotra, et al.
AIDS Research and Therapy|August 30, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD studyGregory D Huhn, Joseph J Eron, Pierre-Marie Girard, et al.
Lancet (London, England)|August 8, 2006
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialJoseph Eron, Patrick Yeni, Joseph Gathe, et al.
The Lancet. HIV|November 20, 2019
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trialJean-Michel Molina, Kathleen Squires, Paul E Sax, et al.
The Lancet. HIV|May 17, 2021
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trialJean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, et al.
European Journal of Immunology|May 10, 2024
HIV rebound in HIV controllers is associated with a specific fecal microbiome profileYanhui Cai, Ondrej Podlaha, Steven G Deeks, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
The Lancet. HIV|March 30, 2018
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean-Michel Molina, Kathleen Squires, Paul E Sax, et al.
Lancet (London, England)|July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksPaul E Sax, Edwin DeJesus, Anthony Mills, et al.
Pageof 16